Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $91.55 Average PT from Analysts

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has been given an average recommendation of “Moderate Buy” by the ten analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $91.55.

A number of research analysts recently weighed in on RARE shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $107.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, April 5th. JPMorgan Chase & Co. lifted their price objective on Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, March 18th. Canaccord Genuity Group increased their target price on shares of Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the stock a “buy” rating in a research report on Wednesday, February 21st. Robert W. Baird raised their price target on shares of Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the company an “outperform” rating in a report on Tuesday, January 30th. Finally, Wedbush boosted their price objective on shares of Ultragenyx Pharmaceutical from $47.00 to $48.00 and gave the stock a “neutral” rating in a research note on Friday, February 16th.

Insider Activity

In related news, EVP Karah Herdman Parschauer sold 3,756 shares of the stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $53.76, for a total value of $201,922.56. Following the completion of the transaction, the executive vice president now owns 67,340 shares of the company’s stock, valued at $3,620,198.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Ultragenyx Pharmaceutical news, insider John Richard Pinion sold 4,173 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $53.76, for a total transaction of $224,340.48. Following the sale, the insider now owns 89,268 shares in the company, valued at $4,799,047.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Karah Herdman Parschauer sold 3,756 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $53.76, for a total value of $201,922.56. Following the transaction, the executive vice president now directly owns 67,340 shares in the company, valued at approximately $3,620,198.40. The disclosure for this sale can be found here. Insiders sold 31,974 shares of company stock worth $1,639,721 over the last ninety days. Corporate insiders own 6.80% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several large investors have recently added to or reduced their stakes in the company. Raymond James & Associates grew its position in shares of Ultragenyx Pharmaceutical by 46.0% during the 1st quarter. Raymond James & Associates now owns 13,882 shares of the biopharmaceutical company’s stock valued at $1,008,000 after buying an additional 4,373 shares during the last quarter. US Bancorp DE raised its position in Ultragenyx Pharmaceutical by 14.6% in the first quarter. US Bancorp DE now owns 8,611 shares of the biopharmaceutical company’s stock worth $625,000 after acquiring an additional 1,097 shares in the last quarter. Bank of Montreal Can raised its holdings in shares of Ultragenyx Pharmaceutical by 22.7% in the 1st quarter. Bank of Montreal Can now owns 40,319 shares of the biopharmaceutical company’s stock worth $2,927,000 after purchasing an additional 7,469 shares in the last quarter. MetLife Investment Management LLC acquired a new position in Ultragenyx Pharmaceutical in the first quarter worth approximately $252,000. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Ultragenyx Pharmaceutical by 44.1% in the first quarter. Dimensional Fund Advisors LP now owns 463,996 shares of the biopharmaceutical company’s stock valued at $33,693,000 after buying an additional 141,945 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE stock opened at $42.87 on Tuesday. Ultragenyx Pharmaceutical has a 1-year low of $31.52 and a 1-year high of $54.98. The firm’s 50-day simple moving average is $48.22 and its 200-day simple moving average is $43.39. The firm has a market cap of $3.53 billion, a P/E ratio of -5.15 and a beta of 0.65.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.65) by $0.13. Ultragenyx Pharmaceutical had a negative net margin of 139.70% and a negative return on equity of 369.54%. The company had revenue of $127.39 million for the quarter, compared to the consensus estimate of $119.38 million. During the same quarter last year, the firm posted ($2.16) earnings per share. Ultragenyx Pharmaceutical’s revenue was up 23.3% on a year-over-year basis. Analysts expect that Ultragenyx Pharmaceutical will post -6.34 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.